Bavarian Nordic (OTCMKTS:BVNRY) was downgraded by stock analysts at ValuEngine from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Saturday.

Separately, Zacks Investment Research raised shares of Bavarian Nordic from a “sell” rating to a “hold” rating in a report on Monday, November 20th.

Shares of Bavarian Nordic (OTCMKTS BVNRY) opened at $12.56 on Friday. Bavarian Nordic has a one year low of $11.06 and a one year high of $22.70. The stock has a market cap of $1,206.25, a PE ratio of 16.97 and a beta of -1.72. The company has a quick ratio of 9.89, a current ratio of 10.27 and a debt-to-equity ratio of 0.01.

Bavarian Nordic (OTCMKTS:BVNRY) last issued its earnings results on Wednesday, November 8th. The company reported $0.54 earnings per share (EPS) for the quarter. Bavarian Nordic had a net margin of 26.62% and a return on equity of 21.19%. equities analysts predict that Bavarian Nordic will post 0.5 earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “Bavarian Nordic (BVNRY) Downgraded by ValuEngine to Sell” was originally reported by Watch List News and is the sole property of of Watch List News. If you are reading this article on another site, it was illegally copied and republished in violation of US and international copyright and trademark law. The correct version of this article can be viewed at

Bavarian Nordic Company Profile

Bavarian Nordic A/S, a biotechnology company, develops, manufactures, and commercializes a portfolio of novel vaccines for the prevention and treatment of life-threatening infectious diseases and cancer. The company markets non-replicating smallpox vaccine under the IMVAMUN and IMVANE names. It is also developing MVA-BN Filo that is in Phase III trial for the treatment of Ebola and Marburg; MVA-BN RSV, which is in Phase II clinical development stage for the prevention of respiratory syncytial virus; and MVA-BN HPV that is in preclinical development stage to treat human papillomavirus.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Bavarian Nordic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bavarian Nordic and related companies with's FREE daily email newsletter.